Expand ADCT Menu
ADCT MENU

ADCT Latest Press Releases

-- April 4, 2024 --

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Globe Newswire 7:00 AM

-- April 3, 2024 --

ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024 Globe Newswire 7:00 AM

-- April 1, 2024 --

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan Globe Newswire 4:05 PM

-- March 13, 2024 --

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates Globe Newswire 7:00 AM

-- March 6, 2024 --

ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit Globe Newswire 7:15 AM
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024 Globe Newswire 7:00 AM

-- March 5, 2024 --

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting Globe Newswire 5:45 PM

-- February 27, 2024 --

ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference Globe Newswire 7:00 AM

-- January 4, 2024 --

ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards Globe Newswire 7:15 AM
ADC Therapeutics Provides Business Updates Globe Newswire 7:00 AM

-- December 12, 2023 --

ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL) Globe Newswire 5:15 AM

-- November 20, 2023 --

Sobi to present new data at ASH 2023 Annual Meeting PRNewswire 2:36 AM